Financial Performance - The company's operating revenue for 2025 was CNY 3,241,380,430.62, a decrease of 2.82% compared to CNY 3,335,283,008.68 in 2024[16] - The net profit attributable to shareholders for 2025 was CNY 68,418,663.02, down 23.44% from CNY 89,371,134.24 in 2024[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 63,434,024.61, a decrease of 17.65% compared to CNY 77,028,485.76 in 2024[16] - Basic earnings per share for 2025 were CNY 0.14, a decline of 22.22% from CNY 0.18 in 2024[16] - The diluted earnings per share also stood at CNY 0.14, reflecting a 22.22% decrease compared to CNY 0.18 in 2024[16] - The total profit for 2025 was CNY 108 million, down 29.08% year-on-year[38] - The company reported a total operating income of ¥777,932,127.47 in Q1, ¥822,549,498.84 in Q2, ¥864,584,512.93 in Q3, and ¥776,314,291.38 in Q4[20] Cash Flow and Assets - The net cash flow from operating activities increased by 50.39% to CNY 347,793,597.26 from CNY 231,264,525.09 in 2024[16] - Total assets at the end of 2025 reached ¥5,418,295,716.77, an increase of 3.56% compared to the end of 2024[17] - Cash and cash equivalents rose to 449,964,450.38 CNY, accounting for 8.30% of total assets, up from 6.52% at the beginning of the year, an increase of 1.78%[58] - Accounts receivable decreased by 2.45%, from 16.51% to 14.06% of total assets, totaling 761,807,949.52 CNY[58] - Inventory increased to 884,642,355.51 CNY, representing 16.33% of total assets, up from 15.09%, a rise of 1.24%[58] Production and Innovation - The company successfully developed and delivered the VA-type high-transmittance high-polarization 2.0 polarizer, marking a significant product innovation[26] - The company has initiated the investment and construction of the 8th production line to address mid-to-high-end capacity bottlenecks[26] - The company operates seven mass production polarizer production lines, with a total annual capacity of approximately 4,000 million square meters[27] - The company has achieved significant growth in sales of MNT and OLED mobile phone polarizers, indicating a shift towards high-value products[38] - The company holds 117 patents, including 22 domestic invention patents and 91 utility model patents, showcasing its strong R&D capabilities[32] Market and Competitive Landscape - The company faces risks including macroeconomic risks, market risks, raw material risks, and intensified competition risks[3] - The company aims to maintain its competitive advantage in the polarizer industry by focusing on large-size products and advancing technology in OLED and automotive applications[71] - The global demand for polarizers is expected to grow from 605 million square meters in 2024 to 685 million square meters by 2028, representing a cumulative growth of 13.41%[71] Governance and Management - The company held 6 shareholder meetings in 2025, ensuring compliance with legal requirements and protecting minority investors' voting rights[81] - The board of directors convened 13 meetings in 2025, adhering to regulations and enhancing decision-making through specialized committees[82] - The company maintained independence from its controlling shareholders, ensuring a complete separation in operations, finance, and assets[84] - The company has established a robust risk management framework to support stable development[81] Employee and Training Initiatives - The company emphasizes employee training and development, with initiatives aimed at enhancing professional skills and overall capabilities[110] - The company has established a comprehensive employee welfare system, including critical illness and accident insurance, to enhance employee security and satisfaction[122] - The total number of employees receiving salaries during the reporting period was 1,404, reflecting a stable workforce[108] Environmental and Compliance Practices - The company has maintained compliance with environmental regulations, with no major environmental incidents reported during the reporting period[123] - The company actively promotes green office practices and has improved its waste gas and wastewater treatment processes to reduce carbon emissions[124] - The company is included in the list of enterprises required to disclose environmental information, with one subsidiary listed[120] Audit and Financial Reporting - The audit opinion for the financial report is a standard unqualified opinion, issued by Deloitte Huayong Accounting Firm[176] - The audit report was issued on March 26, 2026, by Deloitte Huayong Certified Public Accountants[194] - The audit procedures included testing internal controls related to polarizer sales, evaluating sales contracts, and verifying revenue recognition through supporting documents[184]

Financial Performance - The company's operating revenue for 2025 was CNY 4,516,760,968.30, representing a 0.84% increase compared to CNY 4,479,343,609.52 in 2024 [18]. - Net profit attributable to shareholders for 2025 was CNY 104,961,138.43, a significant turnaround from a loss of CNY 250,277,338.89 in 2024, marking a 141.94% improvement [18]. - The net profit after deducting non-recurring gains and losses for 2025 was CNY 79,178,273.38, up 128.48% from a loss of CNY 277,969,791.37 in 2024 [18]. - The company's cash flow from operating activities for 2025 was CNY 478,304,725.36, down 13.63% from CNY 553,786,774.78 in 2024 [18]. - Basic and diluted earnings per share for 2025 were both CNY 0.10, compared to a loss of CNY 0.23 in 2024, reflecting a 143.48% increase [18]. - Total assets at the end of 2025 were CNY 8,995,527,599.51, a decrease of 8.14% from CNY 9,792,773,457.42 at the end of 2024 [18]. - The company's total net assets attributable to shareholders at the end of 2025 were CNY 6,792,505,837.86, a slight decrease of 0.38% from CNY 6,818,402,052.61 at the end of 2024 [18]. - The overall revenue for the company in 2025 was approximately 4.517 billion yuan, reflecting a growth of 0.84% compared to 2024 [61]. - The energy digitalization business generated revenue of 2.107 billion yuan, showing a year-on-year decline of approximately 1.88% [54]. - The company's energy internet business achieved revenue of 1.977 billion yuan, a year-on-year increase of approximately 9.56% [57]. Dividend and Profit Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of RMB 1.90 per 10 shares (tax included) based on a total of 1,078,235,821 shares [4]. - The company plans to distribute cash dividends of 2.50 yuan (including tax) per 10 shares, totaling approximately 270 million yuan (including tax) based on a distribution base of 1,078,235,821 shares after repurchased shares [121]. - The company reported that cash dividends exceeding 300 million yuan were distributed on April 23, 2024, based on a distribution base of 1,083,541,993 shares [120]. - The cash dividend for the current period amounts to 204,864,805.99 yuan, representing 100% of the total profit distribution [158]. - The company aims for a minimum cash dividend of 15% of the distributable profit, with a cumulative cash distribution over the last three years being at least 30% of the average annual distributable profit [155]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with key personnel affirming the integrity of the annual report [3]. - The company is committed to ensuring that all board members attended the meeting to discuss the annual report, highlighting governance transparency [4]. - The company has revised its internal regulations and no longer has a supervisory board, with its functions now performed by the audit committee of the board [124]. - The company emphasizes information disclosure and investor relations management, ensuring timely and accurate information release according to regulatory requirements [125]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, and operations, ensuring a complete business system [128]. - There are no significant discrepancies between the company's governance practices and the regulations set by the China Securities Regulatory Commission [127]. - The company has established an internal audit system to enhance operational compliance and risk control [125]. - The company has committed to timely and adequate disclosure of relevant commitments and has established a compensation fund for investors in case of losses due to non-compliance [176]. Strategic Direction and Market Expansion - The company is transitioning from a software service provider to an AI-driven energy service and operation provider, leveraging over 28 years of experience in the energy sector [26]. - The company has formed a strategic partnership with Alipay to create an online payment service platform for electricity, water, and gas, targeting a new market for energy operations aimed at hundreds of millions of households and small businesses [31]. - The company is actively involved in the construction of zero-carbon parks, with the first batch of 52 national-level parks announced, addressing urgent low-carbon transformation needs through the deployment of photovoltaic and energy storage facilities [36]. - The company is positioned to benefit from the ongoing reforms in the electricity market, with a focus on creating a unified national electricity market system by 2030, enhancing market activity and price signal effectiveness [38]. - The company is actively pursuing market expansion and innovation in business models driven by AI technology, which is expected to create significant market opportunities [104]. - The company intends to actively explore new markets in Africa and South Asia, aiming for rapid growth in overseas digitalization business by diversifying its product line and expanding market regions [109]. Research and Development - The company has achieved a research and development investment of approximately ¥527 million in 2025, representing 11.67% of its operating revenue [79]. - The company has developed a low-code platform that reduces the 3D project development cycle by over 50% [78]. - The company has established a quantitative factor library to support data-driven decision-making [75]. - The company has developed 38 algorithms to enhance electricity demand forecasting capabilities [75]. - The company is focusing on developing a low-code application platform, DATAIDE, to improve delivery efficiency and reduce development time [74]. Employee and Management - The total number of employees at the end of the reporting period is 5,202, with 3,055 in the parent company and 2,147 in major subsidiaries [149]. - The total employee compensation for the reporting period amounts to ¥793,771,850.88, representing 30.03% of the company's operating costs [150]. - The company has implemented a compensation policy aimed at aligning employee interests with company performance, including a stock incentive plan [150]. - The company has a comprehensive salary system for directors and senior management, ensuring compliance with relevant laws and regulations [141]. - The number of R&D personnel decreased by 4.80% from 3,146 in 2024 to 2,995 in 2025, while the proportion of R&D personnel increased by 0.90% [79]. Charitable Activities and Social Responsibility - The company donated RMB 50,000 to earthquake relief efforts in Tibet following the January 2025 earthquake [166]. - A total of 15 community support activities were conducted for elderly individuals in need, benefiting 264 people throughout the year [166]. - In January 2025, the company conducted 20 humanitarian care activities benefiting 272 terminally ill patients in collaboration with various medical institutions [167]. - In March 2025, the company donated 320,000 RMB to support the development of the first domestic sociology textbook on death for higher education [167]. - The company has actively participated in various charitable activities, including supporting children in need and promoting mental health awareness among vulnerable groups [170].

包头东宝生物技术股份有限公司 2025 年年度报告全文 包头东宝生物技术股份有限公司 2025 年年度报告 2026-007 【披露时间】 1 包头东宝生物技术股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律 责任。 公司负责人王爱国、主管会计工作负责人郝海青及会计机构负责人(会计 主管人员)杜丽声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告如有涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承 诺。投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。 公司在本报告"第三节管理层讨论与分析"之"十一、公司未来发展的 展望"部分详细描述了公司未来经营中可能存在的风险及应对措施，敬请投 资者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以 2025 年度权益分派股 权登记日公司总股本扣除已回购股份后持有股份为基数，向全体股东每 10 股 ...

证券代码：002532 证券简称：天山铝业 公告编号：2026-021 天山铝业集团股份有限公司 2026 年第一季度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2026 年 1 月 1 日至 2026 年 3 月 31 日。 | 项目 | 本报告期 | | 上年同期 | | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | 220,000 | | 105,809.3 | | | 比上年同期增长 | 107.92% | | | 扣除非经常性损益后的净利润 | 218,500 | | 103,827.54 | | | 比上年同期增长 | 110.45% | | | 基本每股收益（元/股） | 0.48 | | 0.23 | 二、与会计师事务所沟通情况 本次业绩预告未经注册会计师预审计。 三、业绩变动原因说明 公司业绩增长的主要原因为：140 万吨电解铝绿色低碳能效提升项目部分产能投产，电解 铝产销量同比增长约 10%；同时，电解铝产品销售价格同比上涨约 17%，生产成本有效控 ...

天山铝业集团股份有限公司 2025 年年度报告 2026年３月 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整,不存在虚假记载、误导性陈述或重大遗漏,并承担个别和连带的法律责 任。 公司负责人曾超林、主管会计工作负责人胡春华及会计机构负责人（会 计主管人员）朱弘松声明:保证本年度报告中财务报告的真实、准确、完 整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及未来计划等前瞻性陈述,不构成公司对投资者的实质承 诺,投资者及相关人士均应当对此保持足够的风险认识,并且应当理解计划、 预测与承诺之间的差异,敬请投资者注意投资风险。 公司已在本报告中详细描述公司可能面临的风险,敬请投资者予以关注, 详见本报告第三节"管理层讨论与分析"章节中第十一节"公司未来发展的 展望"章节中第四点"公司面临的主要风险和应对措施"。 公司经本次董事会审议通过的利润分配预案为:以公司总股本扣除回购 专用账户中股数后的 4,589,876,885 股为基数,向全体股东每 10 股派发现金 红利 2.5 元（含税），送红股 0 股（含税），不以公积金转增股 ...

北京宇信科技集团股份有限公司 2025 年年度报告 公告编号：2026-007 股票代码：300674 披露日期：2026 年 3 月 30 日 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律 责任。 公司负责人洪卫东、主管会计工作负责人戴士平及会计机构负责人(会计 主管人员)梁文芳声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告所涉及的未来发展计划等前瞻性陈述，不构成公司对投资者的实 质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解 计划、预测与承诺之间的差异。公司在发展过程中，可能存在市场竞争风险、 服务对象行业及销售客户相对集中的风险、技术与产品开发质量的风险、侵 权风险、核心技术人员流失的风险、季节性风险、监管风险、海外市场风险 等，具体请参阅本报告"第三节、管理层讨论与分析"之"十一、公司未来 发展的展望（二）公司面临的风险及应对措施"部分。敬请广大投资者注意 投资风险 ...

广东银禧科技股份有限公司 2025 年年度报告全文 广东银禧科技股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律 责任。 公司负责人谭文钊、主管会计工作负责人顾险峰及会计机构负责人(会计 主管人员)蔡洁声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 广东银禧科技股份有限公司 2025 年年度报告 2026 年 3 月 1 公司在生产经营中可能存在原材料价格供应及价格变动、产品市场竞争 加剧等风险，有关风险因素内容与对策举措已在本报告"第三节 管理层讨论 与分析"之"十一、公司未来发展的展望"部分予以描述，敬请广大投资者 注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 473,754,685 为基数， 向全体股东每 10 股派发现金红利 1 元（含税），送红股 0 股（含税），以资本 公积金向全体股东每 10 股转增 0 股。 2 | 第一节 重要提示、目录和释义 | | 2 | ...

山东新华制药股份有限公司 二零二五年年度报告 2026 年 3 月 27 日 | 1 | 公司基本情况简介………………………………………………………………………… | 4 | | --- | --- | --- | | 2 | 会计数据和业务数据摘要…………………………………………………………… | 6 | | 3 | 股份变动及股东情况…………………………………………………………………… | 8 | | 4 | 董事、高级管理人员和员工情况……………………………………………… | 11 | | 5 | 公司管治及内部控制报告…………………………………………………………… | 16 | | 6 | 股东会简介……………………………………………………………………………………… | 31 | | 7 | 董事长报告……………………………………………………………………………………… | 32 | | 8 | 经营管理研讨与分析…………………………………………………………………… | 35 | | 9 | 董事会报告……………………………………………………………………………………… | 51 | | 10 | 环境和 ...

Financial Performance - The company's total operating revenue for 2025 was CNY 4,397,768,077.36, representing a year-on-year increase of 10.73% compared to CNY 3,971,757,497.76 in 2024[22]. - The net profit attributable to shareholders of the listed company for 2025 was CNY 64,461,295.12, a decrease of 22.66% from CNY 83,350,850.59 in 2024[22]. - The net cash flow from operating activities increased significantly to CNY 401,766,200.54, up 492.26% from CNY 67,836,219.96 in 2024[22]. - The basic earnings per share for 2025 were CNY 0.15, a decrease of 21.05% compared to CNY 0.19 in 2024[23]. - The company reported a net profit excluding non-recurring gains and losses of CNY 18,420,324.14, down 59.94% from CNY 45,983,500.12 in 2024[22]. - The total operating costs for 2025 were CNY 4,377,228,370.06, up from CNY 3,952,997,293.36 in 2024, reflecting a growth of 10.7%[180]. - The total comprehensive income for 2025 was CNY 64,461,295.12, with a decrease of CNY 4,759,715.88 compared to the previous period[194]. Cash Flow and Investments - The net cash flow from investing activities decreased by 208.04% year-on-year, totaling -¥518,016,042.65, mainly due to increased cash payments for investments[66]. - Cash and cash equivalents at the end of the period reached ¥979,257,438.72, representing 15.86% of total assets, a 35.22% increase compared to the previous period[68]. - The company reported a significant decrease in long-term equity investments by 54.23%, totaling ¥96,327,146.40, which is 1.56% of total assets[68]. - Cash inflow from investment activities totaled CNY 2,192,717,845.14, up from CNY 1,623,351,208.37 in 2024, indicating a growth of about 35.1%[192]. - Cash outflow for investment activities was CNY 2,666,321,398.89, compared to CNY 1,723,788,577.38 in 2024, reflecting an increase of approximately 54.6%[192]. Assets and Liabilities - The total assets of the company at the end of 2025 were CNY 6,175,467,955.66, reflecting a 1.41% increase from CNY 6,089,442,774.30 at the end of 2024[22]. - Total liabilities amounted to CNY 2.90 billion, slightly up from CNY 2.84 billion in the previous year, indicating a growth of approximately 2.4%[175]. - The company’s total non-current assets decreased to CNY 1.23 billion from CNY 1.44 billion, a decline of about 14.6%[174]. - The company’s retained earnings increased to CNY 868.85 million from CNY 837.73 million, reflecting a growth of approximately 3.7%[175]. Research and Development - R&D expenses increased by 7.28% to CNY 175,850,740.70, reflecting ongoing investment in innovation[46]. - The company is actively responding to national environmental policies and has increased R&D efforts to optimize engine performance and compliance[37]. - The company plans to increase R&D investment to develop new technologies and products, particularly in response to stricter national emission regulations[81]. Market Position and Strategy - The company maintained a strong market position in the small and medium power diesel engine segment, covering a power range of 20 to 360 horsepower[41]. - The company aims to strengthen market expansion and increase market share by focusing on customer needs and enhancing brand reputation[38]. - The company is actively expanding its overseas business, enhancing the reputation of export products, and increasing sales in international markets[80]. Governance and Compliance - The company has established independent financial and operational structures, ensuring no interference from the controlling shareholder in its decision-making processes[88]. - The company maintains a strict governance structure, ensuring compliance with laws and regulations while enhancing information disclosure and investor relations[84]. - The company will strengthen internal governance and ensure compliance with legal and regulatory requirements to enhance investor relations and protect shareholder rights[79]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 43,628, an increase from 40,932 at the end of the previous month[148]. - The largest shareholder, Anhui Quanchai Group Co., Ltd., holds 82,483,676 shares, representing 18.94% of the total shares[150]. - The company has not reported any changes in its total share capital or share structure during the reporting period[147]. Employee and Management Compensation - The total pre-tax compensation for directors and senior management amounted to 675.21 million yuan[89]. - The company has established a performance evaluation and incentive mechanism for senior management, with a salary structure including a basic salary, performance salary, and a long-term incentive income calculated at 30% of the total basic and performance salary[116]. - The company employs a total of 2,675 staff, including 2,125 in the parent company and 550 in major subsidiaries[99].

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of 941,601,686.09 yuan for the fiscal year 2025[6]. - As of the end of the reporting period, the profit available for distribution to shareholders by the parent company was 2,494,355,715.15 yuan[6]. - The company plans to distribute a cash dividend of 2.00 yuan (including tax) for every 10 shares, totaling 268,234,538.40 yuan (including tax) based on a total share capital of 1,341,172,692 shares as of December 31, 2025[6]. - The company's operating revenue for 2025 was approximately ¥9.36 billion, a decrease of 14.39% compared to ¥10.94 billion in 2024[23]. - The total profit for 2025 was approximately ¥1.33 billion, down 20.65% from ¥1.67 billion in 2024[23]. - The net profit attributable to shareholders for 2025 was approximately ¥941.60 million, a decline of 13.11% from ¥1.08 billion in 2024[23]. - The basic earnings per share for 2025 was ¥0.7021, representing a decrease of 13.11% compared to ¥0.8080 in 2024[24]. - The weighted average return on equity for 2025 was 6.97%, down 1.48 percentage points from 8.45% in 2024[24]. - The net cash flow from operating activities for 2025 was approximately ¥1.70 billion, a decrease of 24.73% from ¥2.26 billion in 2024[23]. - The total assets at the end of 2025 were approximately ¥19.23 billion, a decrease of 3.65% from ¥19.96 billion at the end of 2024[23]. - The company reported non-recurring gains and losses totaling approximately ¥92.42 million for 2025, compared to ¥40.34 million in 2024[28]. - The company's total profit for the reporting period was CNY 1.328 billion, a year-on-year decrease of 20.65%[53]. - Net profit attributable to shareholders was CNY 942 million, down 13.11% year-on-year[53]. - Operating revenue decreased by 14.39% to CNY 9.363 billion compared to CNY 10.938 billion in the previous year[54]. - Operating costs fell by 4.79% to CNY 6.327 billion, but the decline was less than the revenue drop[54]. - The cash flow from operating activities was CNY 1.698 billion, a decrease of 24.73% year-on-year[54]. Risk Management - There are no significant risks that materially affect the company's production and operations during the reporting period[10]. - The company has no unfulfilled losses that would impact dividend distribution[7]. - The audit report issued by Tianjian Accounting Firm was a standard unqualified opinion[5]. - The board of directors and senior management guarantee the authenticity, accuracy, and completeness of the annual report[3]. - The company has no non-operating fund occupation by controlling shareholders or related parties[8]. - The company has no violations of decision-making procedures for providing guarantees[8]. - The company emphasizes the importance of understanding the risks associated with forward-looking statements regarding future plans and strategies[7]. Operational Highlights - The company operates in various pharmaceutical sectors, including active pharmaceutical ingredients and health products, with over 30 dosage forms[33]. - The company's raw materials and pharmaceutical intermediates segment achieved sales revenue of 4.476 billion yuan, a year-on-year decrease of 13.89%, accounting for 47.81% of total revenue, an increase of 0.28 percentage points year-on-year[38]. - Key products in the raw materials segment, such as 7-ACA, urinary biochemical products, and crude cefotaxime sodium, saw significant sales growth of 114.74%, 44.09%, and 43.69% respectively[38]. - The formulation segment reported sales revenue of 4.622 billion yuan, down 15.21% year-on-year, representing 49.36% of total revenue, a decrease of 0.48 percentage points year-on-year[39]. - The company adopted a "price for volume" strategy in the cardiovascular drug sector, leading to steady sales growth in products like sustained-release nifedipine and benazepril[39]. - The overall demand for cephalosporin formulations weakened, resulting in a 17.45% year-on-year decline in revenue from anti-infection formulations[39]. - New product approvals in recent years contributed to revenue growth, although overall performance in the nervous system medication sector saw a significant decline of 18.79% due to market competition[39]. Research and Development - The company received 45 production/supplement application approvals and initiated 50 new R&D projects in 2025, including 50 patent applications, of which 29 were invention patents[47]. - The company secured 6 products in the 11th batch of national drug procurement, effectively stabilizing market share[47]. - The company achieved a procurement rate of 47.24%, leveraging scale purchasing advantages to stabilize the supply chain[48]. - The company expanded its international registration with 12 new overseas registration certificates, including 10 in countries along the "Belt and Road" initiative[47]. - The company is focusing on "innovation-driven" development, emphasizing five core therapeutic areas: anti-infection drugs, cardiovascular drugs, anesthetics and psychotropic drugs, anti-tumor and immune modulators, and metabolic and endocrine drugs[35]. - The company has developed key antibiotics including Amoxicillin and Azithromycin, which are used for treating infections caused by resistant bacteria[86]. - The company is focusing on the development of new antibiotics, including Cefuroxime Axetil tablets, which are indicated for bacterial infections[87]. - The company is actively pursuing research in hormone therapies, such as injectable Methylprednisolone Acetate, for endocrine disorders[87]. - The company is committed to expanding its market presence through the introduction of new products and technologies in the pharmaceutical sector[87]. Marketing and Sales Strategy - The marketing strategy includes participation in national and provincial volume-based procurement to meet clinical medication needs and expand online retail market coverage[37]. - The company has diversified its sales channels for OTC drugs, utilizing commercial distribution, direct supply to chains, and e-commerce platforms[110]. - The company has implemented a shift from a resource-consuming sales model to an efficiency-driven model, focusing on integrated marketing strategies and budget control[112]. - The company is actively participating in national and provincial centralized drug procurement to meet clinical medication needs[109]. - The company continues to expand its product line in the health sector through various sales models, combining online and offline strategies[110]. Corporate Governance - The company has established a comprehensive marketing management organization to adapt to national drug procurement policies and enhance market access strategies[109]. - The company has implemented a rigorous performance evaluation mechanism for senior management, linking compensation to performance metrics, ensuring that salary increases are tied to performance improvements[173]. - The company has established a performance assessment system for internal directors and senior management, which considers individual job responsibilities and assessment results[147]. - The company has maintained a high standard of information disclosure, with 157 announcements made in 2025, achieving an A-level rating for information disclosure from the Shanghai Stock Exchange for four consecutive years[134]. - The company has established clear guidelines for related party transactions to maintain fairness and transparency[189]. - The company has implemented a closed-loop management mechanism for internal controls, ensuring continuous improvement and compliance[177]. - The company has revised its governance structure, eliminating the supervisory board and transferring its functions to the audit and risk management committee, ensuring effective oversight and compliance[133]. Social Responsibility - Total investment in social responsibility projects amounted to CNY 15.26 million, with CNY 10 million allocated for cash donations and CNY 5.26 million for material contributions[182]. - Total investment in poverty alleviation and rural revitalization projects reached CNY 200.74 million, including a CNY 990,000 donation to support local party building and industrial development in Jilin Province[182]. - The company engaged in targeted procurement of assistance products valued at CNY 967,400 through initiatives like "purchase instead of donation" throughout the year[182]. Compliance and Legal Matters - The company has maintained compliance with all regulatory requirements and has not faced any penalties[194]. - The company faced no major litigation or arbitration matters during the reporting period[192]. - The company has not made any changes to performance commitments or forecasts during the reporting period[190]. - The company has committed to avoiding any business competition with its controlled enterprises, ensuring priority rights for its subsidiaries[189].